글로벌 단핵구증 진단 시장 – 2029년까지의 산업 동향 및 예측

 단핵구증 진단 시장 분석 및 규모

질병통제예방센터에 따르면 2002년부터 2018년까지 전염성 단핵구증(IM) 사례가 약 23,780건 발생했으며, 전반적인 발생률은 10만 인년(p-yr)당 104.2건이었습니다. IM 진단의 유병률은 가장 어린 연령대에서 가장 높았고 나이가 들면서 감소했습니다. 다른 인종/민족 그룹과 비교했을 때, 비히스패닉계 백인 군인의 IM 진단 발생률이 더 높았습니다(10만 인년당 123.4건). 신병 중 IM 진단 발생률은 다른 입대 인원(10만 인년당 106.0건)의 3.4배, 장교(10만 인년당 64.7건)의 5.6배였습니다. 전염성 단핵구증(IM) 발병률이 증가함에 따라 이를 진단하는 수요도 늘어나 성장세를 보이고 있습니다.

Data Bridge Market Research는 단핵구증 진단 시장이 2022년부터 2029년까지의 예측 기간 동안 5.00%의 CAGR에 도달할 것으로 예측한다고 분석했습니다. 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

단핵구증 진단 시장 범위 및 세분화

Market Definition

Mononucleosis is an infectious disease caused by epstein barr virus that spreads through saliva. Early diagnosis allows for effective treatment of the infection, necessitating the need for mononucleosis diagnostics. The benefits of mononucleosis diagnostics, such as precise diagnosis, perfect detection, and accurate results, may lead to good growth opportunities. All of these factors may bode well for the growth of the mononucleosis diagnostic market.

Global Mononucleosis Diagnostic Market Dynamics

Drivers

• Technological advancements act as a promising driver

Various novel technological advancements are occurring that can diagnose the infection faster than available on the market. For instance, Roche announced in 2020 that the USFDA had approved the Cobas EBV test, the first in-vitro quantitative diagnostic test in the US for the diagnosis of EBV Epstein-Barr Virus. This is a huge success for the healthcare industry and professionals because it will make it much easier to monitor patients who are at risk from this virus because it will perform a large number of tests in a short period of time.

• Increasing adolescent population is laying the foundation for expansion

Increasing adolescent population globally is also one of the major factor leading to growth of the market as mononucleosis is most common among teens and adults. More than half of all adolescents globally live in Asia. South Asia has nearly 350 million adolescents than any other region. It is followed by East Asia and the Pacific with over 300 million. The adolescent population of either of these regions dwarfs that of any other region in the world. According to World Health Organization (WHO) report, there are nearly 1.2 billion adolescents (10-19 years old) worldwide. In some countries, adolescents account for a quarter of the population and the number of adolescents is expected to rise through 2050, mainly in low- and middle-income countries (LMICs) where close to 90% of 10- to 19-year-olds live.

Opportunities

• Rising incidence of infectious mononucleosis is propelling growth

The rising incidence of infectious mononucleosis (IM), growing rising awareness and knowledge about mononucleosis, and increasing research and development activities for IM diagnosis and treatment are the major factors that are increasing the global mononucleosis diagnostic market.

Restraints/Challenges

• High cost of mononucleosis diagnostic will challenge the market

High cost of mononucleosis diagnostic and the low adoption rate in emerging and underdeveloped countries will obstruct the market's growth rate. There are some limitations associated with mononucleosis diagnostic tests which are expected to hamper the market's growth during the forecast period. There are only three tests that can diagnose mononucleosis and that is very low in regard to the rate by which the infectious mononucleosis is growing.

This mononucleosis diagnostic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the mononucleosis diagnostic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent developments

• In September 2019, Roche has launched two tests for use on the automated cobas 6800/8800 Systems in countries where the CE mark is accepted. The cobas EBV (Epstein-Barr virus) and cobas BKV (BK virus) Tests provide clinical decision-making with reliable, standardised, high-quality results to help manage the risk of infection and improve the management of severely immunocompromised transplant patients.
• In July 2019, NeuMoDx Molecular, a sample-to-result molecular diagnostics company focusing on central laboratory customers, has introduced CE-IVD assays for Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV), both of which can cause infectious mononucleosis and other illnesses.

Global Mononucleosis Diagnostic Market Scope

The mononucleosis diagnostic market is segmented on the basis of test type and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

• Epstein Barr Virus (EBV) Antibody Test
• Monospot Test
• Complete Blood Count Test

 End-User

• Hospitals
• Laboratories
• Others

Mononucleosis Diagnostic Market Regional Analysis/Insights

The mononucleosis diagnostic market is analysed and market size insights and trends are provided by country, test type and end-user as referenced above.

The countries covered in the mononucleosis diagnostic market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the mononucleosis diagnostic market because of the presence of well-developed healthcare infrastructure and favourable reimbursement policies in the region, owing to rising incidence rate of infectious mononucleosis (IM), advancement in healthcare infrastructure supporting novel testing, and increasing research and development activities by major players in this region. 

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising adolescent population and rising incidence of infectious mononucleosis (IM) in the region, owing to the rising adolescent population in this region. According to the UNICEF data, over half of all adolescents across the world live in Asia, and South Asia is home to the largest number of adolescents in any region in the world.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The mononucleosis diagnostic market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for mononucleosis diagnostic market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the mononucleosis diagnostic market. The data is available for historic period 2010-2020.

Competitive Landscape and Mononucleosis Diagnostic Market Share Analysis

단핵구증 진단 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 단핵구증 진단 시장과 관련된 회사의 초점에만 관련이 있습니다.

단핵구증 진단 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 애벗(미국)
• 다이이치 산쿄 주식회사(일본)
• 바이츠만 과학 연구소(이스라엘)
• Biotest AG(독일)
• Bio-Rad Laboratories, Inc. (미국)
• 젠자임(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 존슨앤존슨 서비스 주식회사(미국)
• BD(미국)
• DiaSorin Molecular LLC(미국)
• Beckman Coulter, Inc. (미국)
• bioMérieux (프랑스)
• 지멘스(독일)
• 세키스이 다이어그노스틱스(미국)
• ELITechGroup(프랑스)
• 카디널 헬스(미국)
• Immunostics Inc. (미국)
• 메리디안 바이오사이언스(미국)
• Thermo Fischer Scientific Inc. (미국)

SKU-56011